CAS · 61379-65-5
Product Overview
Rifapentine is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance: | Brick-red to Dark red crystalline powder |
|---|---|
| Assay: | 93.5% min (Calculated on the dried basis) |
| Solubility: | Soluble in chloroform/methanol, slightly soluble in ethanol/acetone/n-butyl alcohol, insoluble in water |
| Identification: | IR & HPLC positive |
| pH: | 4.0–8.0 |
| Any individual impurity: | 1.0% max |
| Sum of impurities: | 3.0% max |
| Heavy metals: | 20 ppm max |
| Water: | 1.5%–5.0% |
| Residue on ignition: | 0.2% max |
| Ethanol: | 1.0%–3.5% |
| Butyl alcohol: | 1.0% max |
Applications
1. Treatment of Tuberculosis (TB)
● Rifapentine is used in combination with other anti-tubercular agents such as isoniazid or moxifloxacin for the treatment of active TB.
● It is part of short-course regimens to enhance patient adherence due to less frequent dosing.
2. Latent TB Infection (LTBI)
● One of its most important applications is in the treatment of latent TB, preventing the progression to active disease.
● The 3HP regimen (once-weekly rifapentine + isoniazid for 12 weeks) is endorsed by the CDC and WHO due to its high completion rates and strong efficacy.
● The 1HP regimen (daily rifapentine + isoniazid for 1 month) is another promising short-course regimen under evaluation.
3. HIV-TB Co-infection Treatment
● Rifapentine-based regimens have shown effectiveness in HIV-positive patients, offering simpler and shorter treatment courses compared to traditional TB drugs.
4. Potential Use in Drug-Resistant TB
● Although not the first-line treatment for multidrug-resistant TB (MDR-TB), rifapentine is being explored in clinical studies for its utility in resistance-tailored regimens.
Benefits
1. Long Half-Life and Dosing Convenience
● Rifapentine丨CAS 61379-65-5 has a longer half-life than rifampin (~13–24 hours), enabling less frequent dosing (once or twice weekly), which improves patient adherence.
● This pharmacokinetic profile supports short-course and directly observed therapy (DOT) models.
2. High Potency Against Mycobacterium tuberculosis
● It has potent bactericidal activity against both replicating and semi-dormant TB bacilli.
● Active at lower doses and demonstrates concentration-dependent killing.
3. Improved Treatment Outcomes
● Short-course regimens with rifapentine have shown non-inferiority or superiority compared to traditional longer regimens in clinical trials.
● Lower pill burden and shorter duration contribute to higher treatment completion rates.
4. Strategic Public Health Tool
● As part of global TB eradication strategies, rifapentine is central to new treatment protocols aimed at reducing transmission, improving adherence, and lowering healthcare costs.
Conclusion
Rifapentine丨CAS 61379-65-5 is a vital antibiotic in tuberculosis control, offering shorter, more convenient regimens with improved compliance and treatment outcomes. Its role in both latent and active TB, especially in co-infection with HIV, marks it as a strategic tool in modern infectious disease management. As research continues to expand its use in resistance-prone TB and global health programs, rifapentine is poised to remain a cornerstone of TB therapy.
Previous
Sumatriptan Succinate丨CAS 103628-48-4
Next